12th Mar 2018 09:01
Shares in the biopharmaceutical company focused on immune-mediated diseases fell 34% at
In the phase two study, PR013 did not demonstrate efficacy, leading to the termination of the program.
However, Realm Therapeutics has continued to enrol patients for the Phase Two Atopic Dermatitis study of PR022, and expects to report the third quarter of 2018.
Also, the company's pre-clinical development program in Acne Vulgaris is also progressing, with the intent to file an investigational new drug application with the US Food & Drug Administration to study the drug RLM023 in the fourth quarter of the year.
"While the PR013 results are disappointing, we are extremely pleased with the progress we are making with our dermatology programs, as they continue to be our top priority, Atopic Dermatitis and Acne Vulgaris have different immunologic pathologies and are otherwise unrelated to Allergic Conjunctivitis. We remain confident in our technology's potential to deliver immunomodulatory and anti-inflammatory benefits, and continue to believe that it has potential for application in multiple disease areas," said Chief Executive Officer Alex Martin.
Related Shares:
RLM.L